참고문헌
- Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977;39(2 Suppl):882-890 https://doi.org/10.1002/1097-0142(197702)39:2+<882::AID-CNCR2820390726>3.0.CO;2-X
- Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-284 https://doi.org/10.1200/JCO.1997.15.1.277
- Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991;67:2258-2261 https://doi.org/10.1002/1097-0142(19910501)67:9<2258::AID-CNCR2820670908>3.0.CO;2-G
- Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310-2317 https://doi.org/10.1200/JCO.2005.00.034
- Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys 2001;49:657-664 https://doi.org/10.1016/S0360-3016(00)01399-7
- Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245 https://doi.org/10.1016/0092-8674(92)90644-R
- Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000;2:569-573 https://doi.org/10.1038/35023507
- Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-698 https://doi.org/10.1038/375694a0
- Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 2002;25:454-459 https://doi.org/10.1097/00000421-200210000-00006
- Shimada Y, Imamura M, Shibagaki I, et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 1997;226:162-168 https://doi.org/10.1097/00000658-199708000-00007
- Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 1998;89:221- 227 https://doi.org/10.1111/j.1349-7006.1998.tb00552.x
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 https://doi.org/10.1016/S0092-8674(00)81871-1
- Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330 https://doi.org/10.1016/0092-8674(95)90385-2
- Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-5769
- Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958- 9961 https://doi.org/10.1073/pnas.87.24.9958
- Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993; 53:846-850
- American Joint Committee on Cancer. Manual for staging of cancer. 6th ed. Philadelphia, PA: Lippincott Co. 2002: 57-61
- Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-163 https://doi.org/10.1200/JCO.1996.14.1.156
- Kim JH, Choi EK, Kim SB, et al. Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2001; 50:1-12 https://doi.org/10.1016/S0360-3016(01)01459-6
- Lim JT, Truong PT, Berthelet E, et al. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;57:1328-1335 https://doi.org/10.1016/S0360-3016(03)00751-X
- Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468
- Landers JE, Haines DS, Strauss JF 3rd, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-2750
- Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(10 Suppl):2231-2234
- Meng RD, Shih H, Prabhu NS, George DL, el-Deiry WS. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res 1998;4:251-259
- Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999;12:580-586
- Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003;7:77-86 discussion 86-87 https://doi.org/10.1016/S1091-255X(02)00141-5
- Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J. Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterol Clin Biol 1995;19:465-474
- Shimoji H, Miyazato H, Nakachi A, et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 2000;13:185-190 https://doi.org/10.1046/j.1442-2050.2000.00097.x
- Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003;9:6461-6468
- Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357- 365 https://doi.org/10.1038/ng1093
- Ito T, Kaneko K, Makino R, et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001;36:303-311 https://doi.org/10.1007/s005350170095
- Puglisi F, Di Loreto C, Panizzo R, et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996;49:456-459 https://doi.org/10.1136/jcp.49.6.456
- Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83:7-18 https://doi.org/10.1002/(SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R
- Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined- modality approach. Cancer 2004;100:1859-1867 https://doi.org/10.1002/cncr.20200
- Hur HK, Rha SH, Hong SH. Expression pattern of the Rb protein and its correlation with prognosis in primary lung cancer. Korean J Pathol 1997;31:152-161